In an extension of its partnership with Celltrion Healthcare, pharmaceutical provider Mundipharma has received a license to market and distribute its Truxima cancer treatment drug in Colombia.

(Photo credit: jarmoluk / Pixabay)

Truxima was also launched as the first “biosimilar monoclonal antibody” licensed for the treatment of cancer in various European markets in February, according to the Singapore-headquartered network of drug companies.

Mundipharma added that it is widely authorized in Europe for the treatment of diffuse large B cell Non-Hodgkin’s lymphoma, follicular lymphoma, chronic lymphocytic leukaemia, severe rheumatoid arthritis, and granulomatosis with polyangiitis and microscopic polyangiitis.

Raman Singh, chief executive officer of Mundipharma, said that this is a continuation of the firm’s push to distribute its drugs in new markets. “We are excited to expand our partnership with Celltrion Healthcare to include Truxima in Colombia,” said Singh. “As a core therapy for hematological malignancies, we see it as a good fit with our existing potfolio of products such as Difolta and Zevalin.”